Study: CETP inhibitors

Cholesteryl ester transfer protein (CETP) inhibitors are new class of drugs to treat cardiovascular diseases, specifically CETP inhibitors improves high-density lipoproteins (HDL) level in blood.

Research of CETP inhibitors might have started somewhere around 1990 to 1995 and PD 140195 may be the first compound to evaluated for CETP inhobition.

There are three notable molecules are in development pipeline by different originators. Japan Tabacco and Roche develops JTT-705 (Dalcetrapib), Pfizer (Torcetrapib) and Merck (Anacetrapib).

Pfizer initiated a development of CETP inhibitors which is named Torcetrapib, presently development of Toecetrapib is abandoned due to off-target effect (increase in blood pressure). Delcetrapib and Anacetrapib are presently in progress of positive development. Merck has now presented positive trial data on Anacetrapib  (News).

In next post, i will update patent status on CETP inhibitors (to continue…)

About Guna

Interested to learn things around me
This entry was posted in Drug developments & targets. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s